LAMEA Pet Diabetes Care Market Size, Share & Industry Trends Analysis Report By Animal Type, By Distribution Channel (Veterinary Hospitals & Clinics, Retail Pharmacies, and E-commerce), By Solution, By Country and Growth Forecast, 2022 - 2028

The Latin America, Middle East and Africa Pet Diabetes Care Market is expected to witness market growth of 14.2% CAGR during the forecast period (2022-2028).

These pancreatic cells in diabetic cats and dogs either generate little to no insulin, or the insulin that is released has an aberrant effect. When this occurs, glucose could not enter the cells of the body and starts to build up in the blood. Moreover, the body's cells lack sufficient energy. The result of these two factors together is diabetes mellitus. 
The cornerstone of care for diabetic canines and felines is insulin therapy, and numerous kinds of insulin have been proven to be effective. By enhancing peripheral glucose uptake and inhibiting hepatic glucose synthesis, insulin lowers blood sugar levels. By lowering the cells' glucose tolerance, insulin slows the development of beta-cell apoptosis. In cats, insulin aids in preventing the formation of amyloid plaques from the amyloid polypeptide islet. As a result, insulin is unquestionably the best treatment option for managing diabetes in canine and feline patients.

Between 2016 and 2020, the pet population in the United Arab Emirates (UAE) expanded by over 10,000 animals per year, with the number of large dogs expanding at the quickest rate, at about 6,000 animals per year. Pet "humanization" and the nation's new pet protection law, which was created to prevent pet abandonment and abuse, particularly by nomadic expats, are both driving demand for healthier goods. Between 2016 and 2020, the number of dogs and cats in the UAE increased by over 10,000 apiece, with the huge dog population expanding by about 6,000 animals at the highest rate.

The Brazil market dominated the LAMEA Pet Diabetes Care Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $57.3 million by 2028. The Argentina market is experiencing a CAGR of 14.8% during (2022 - 2028). Additionally, The UAE market is expected to display a CAGR of 13.9% during (2022 - 2028).

Based on Animal Type, the market is segmented into Dogs and Cat. Based on Distribution Channel, the market is segmented into Veterinary Hospitals & Clinics, Retail Pharmacies, and E-commerce. Based on Solution, the market is segmented into Treatment (Insulin Therapy, Insulin Delivery Devices, and Others) and Glucose Monitoring Devices. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Becton, Dickinson and Company, Merck & Co., Inc., Zoetis, Inc., ACON Laboratories, Inc., Allison Medical, Inc., i-SENS, Inc., Trividia Health, Inc., UltiMed, Inc., and Taidoc Technology Corporation.

Scope of the Study

Market Segments Covered in the Report:

By Animal Type

• Dogs
• Cat

By Distribution Channel

• Veterinary Hospitals & Clinics
• Retail Pharmacies
• E-commerce

By Solution

• Treatment
  • Insulin Therapy
  • Insulin Delivery Devices
  • Others
  
  
• Glucose Monitoring Devices

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• Boehringer Ingelheim International GmbH
• Becton, Dickinson and Company
• Merck & Co., Inc.
• Zoetis, Inc.
• ACON Laboratories, Inc.
• Allison Medical, Inc.
• i-SENS, Inc.
• Trividia Health, Inc.
• UltiMed, Inc.
• Taidoc Technology Corporation

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free